Vir Biotechnology, Inc. - Common Stock (VIR)

Gilead deal and 2028 cash runway frame upcoming hepatitis data.

Vir Biotechnology (NASDAQ:VIR) expects to report the first phase 3 results for its experimental hepatitis delta treatment in the fourth quarter of 2026, with data from two additional studies due in the first quarter of 2027, executives said on the company’s third-quarter earnings call. The company

HDV combination therapy achieved 88% viral clearance, advancing toward Phase 3 readouts.

Vir Biotechnology (NASDAQ:VIR) reported second-quarter 2026 results alongside updates on its chronic hepatitis delta and oncology programs, highlighting completed enrollment in a key hepatitis delta study, plans for multiple data readouts, and expanded development activity for its prostate cancer ca

Vir Biotechnology develops immunology-based therapies targeting infectious diseases through global partnerships and scientific innovation.

Vir Biotechnology develops immunology-based therapies for infectious diseases, backed by collaborations and a diversified research pipeline.

Energy Vault Holdings develops modular, grid-scale energy storage systems for utilities and large-scale power users.

Vir Biotechnology develops antibody and RNA-based therapies for infectious diseases, leveraging partnerships and a robust clinical pipeline.

Focused on immunology-based therapies for infectious diseases, this biotech company reported a notable insider sale in recent filings.

Vir (VIR) Q1 2026 Earnings Call Transcript

Focused on infectious disease therapies, this biotech firm reported a notable insider sale amid a year of strong share price gains.

Raymond James analyst Sean McCutcheon upgraded the stock to ‘Strong Buy’ from ‘Outperform’ and lifted his price target to $19 from $12.

The company said its current resources are expected to fund operations into the second quarter of 2028.

Vir Biotechnology (VIR) Earnings Call Transcript

This hot biotech stock could have a lot more room to run.